{"id":"W2189861011","doi":"10.1016/s0140-6736(15)01159-9","title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","year":2015,"lang":"en","type":"article","venue":"The Lancet","topic":"Antifungal resistance and susceptibility","field":"Medicine","cited_by":972,"is_retracted":false,"has_abstract":false,"ca_institutions":"CancerCare Manitoba; University of Manitoba","funders":"","keywords":"Voriconazole; Medicine; Clinical endpoint; Internal medicine; Population; Adverse effect; Clinical trial; Surgery; Gastroenterology; Antifungal","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06051365071297336,"score_gpt":0.3374946320403873,"score_spread":0.2769809813274139,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}